Plandai Products to Assist in Weight Management

Investment and Company Research
Opportunity Research
MICROCAP HOT TOPICS

June 4, 2013

While a great deal of attention has been focused on the treatment and prevention of major diseases such as malaria and other conditions using key green tea extracts such as Epigallocatechin gallate (EGCG), the flagship offering of Plandai Biotechnology Inc. (OTCQB - PLPL - $0.53 - Spec Buy) will soon be used to support weight management. The Company secured a distribution agreement which grants South Africa-based Natural Products the exclusive rights in South Africa to develop and market a weight management product using Plandaí's Phytofare™ Catechin Complex. Natural Products specializes in producing and selling Maxi™ nutriceuticals through an Internet client base and directly to pharmacists and wellness retailers in South Africa.

Green tea has long been recognized for its weight management benefits including fat reduction, increased metabolism and improved endurance during exercise. In fact, a recent Pennsylvania State University study featured in Obesity magazine demonstrated in an animal study that the use of EGCG reduces the ability to absorb fat, thus slowing or reducing the rate of weight gain and also enhances the ability to absorb fat. Mice that were fed EGCG along with a high-fat diet gained weight 45 percent more slowly than the control group of mice eating the same diet without EGCG. This suggests that an EGCG supplement slows the rate of weight gain.

Much has been written in recent years regarding the ever-increasing and resulting health consequences stemming from obesity, costing billions of dollars each year. As a result, even the United States Federal government has elected to help lead initiatives to reduce obesity in the U.S. and worldwide. Studies such as the Penn State tests could serve as a driver in the increased consumption of ECGC and other key green tea-based catechins in order to support weight management. The favorable results of this study illustrate how Plandaí stands to strongly benefit from its relationship with Natural Products to develop and market a weight management product using Plandaí's Phytofare™ Catechin Complex, and its far-reaching sales potential.

Given that Plandaí’s products deliver a bioavailability that is superior to other green tea extracts available today, the Company could eventually emerge as a primary source of ECGC via its Phytofare™ Catechin Complex for use in many weight management products, which represents a revenue opportunity approaching hundreds of millions of dollars worldwide. After all, Plandaí's Phytofare™ Catechin Complex is processed to deliver a highly bioavailable, antioxidant- rich botanical extract at a level many times that of other products available on the market.

For more information, refer to our previous PLPL Reports, Updates and Hot Topics by visiting www.GoldmanResearch.com

Senior Analyst: Robert Goldman
Rob Goldman has over 20 years of investment and company research experience as a senior research analyst and as a portfolio and mutual fund manager. During his tenure as a sell side analyst, Rob was a senior member of Piper Jaffray's Technology and Communications teams. Prior to joining Piper, Rob led Josephthal & Co.'s Washington-based Emerging Growth Research Group. In addition to his sell-side experience Rob served as Chief Investment Officer of a boutique investment management firm and Blue and White Investment Management, where he managed Small Cap Growth portfolios and The Blue and White Fund.

Analyst Certification
I, Robert Goldman, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report.

Disclaimer
This Opportunity Research Hot Topics article was prepared for informational purposes only. Goldman Small Cap Research, (a division of Two Triangle Consulting Group, LLC) produces research via two formats: Goldman Select Research and Goldman Opportunity Research. The Select product reflects the Firm’s internally generated stock ideas while the Opportunity product reflects sponsored research reports. It is important to note that while we may track performance separately, we utilize the same coverage criteria in determining coverage of all stocks in both research formats. While stocks in the Opportunity format may have a higher risk profile, they typically offer greater upside as well. Since April 2012, Goldman Small Cap Research has been compensated $500 per article by a third party. All information contained in this report was provided by the Company or derived from GSCR due diligence. Our analysts are responsible only to the public, and are paid in advance to eliminate pecuniary interests, retain editorial control, and ensure independence. Analysts are compensated on a per report basis and not on the basis of his/her recommendations.

The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research did not make an independent investigation or inquiry as to the accuracy of any information provided by the Company, or other firms. Goldman Small Cap Research relied solely upon information provided by the Company through its filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Such information and the opinions expressed are subject to change without notice. A Goldman Small Cap Research report, update, article, or note is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed.

This publication does not take into account the investment objectives, financial situation, or particular needs of any particular person. This report does not provide all information material to an investor’s decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither Goldman Small Cap Research, nor its parent, is registered as a securities broker-dealer or an investment adviser with FINRA, the U.S. Securities and Exchange Commission or with any state securities regulatory authority.

ALL INFORMATION IN THIS REPORT IS PROVIDED “AS IS” WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THIS INFORMATION, OR FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION.